News Center

Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative

Jul 16, 2019 | News
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin...

Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics

Mar 6, 2019 | News Press Releases
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics...

Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China

Dec 21, 2017 | News
Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China Tracon - Ambrx PR, Final (12.21.17) - CN...

Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

Apr 25, 2017 | News
Primary endpoint of significant reduction in liver fat achieved following 16 weeks of treatment with...

Ambrx closes $45M round of financing

Aug 4, 2016 | News
SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Ambrx, Inc., a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates, today announced that...